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Abstract
Introduction The aim of this study was to assess the long-term
side effects of central nervous system prophylaxis (high-dose
chemotherapy alone vs chemotherapy and CNS radiotherapy)
according to the ALL IC-BFM 2002.
Methods Thirty-tree children aged 6.7–19.9 years have been
studied. The control group consisted of 12 children newly
diagnosed with acute lymphoblastic leukemia. We assessed
subcortical gray matter volume using automatic MRI segmen-
tation and cognitive performance to identify differences be-
tween two therapeutic schemes and patients prior to treatment.
Results Patients treated with chemotherapy and CNS radio-
therapy had smaller hippocampi than two other subgroups and
lower IQ score than patients treated with chemotherapy alone.
Both treated groups, whether with chemotherapy only or in
combination with CNS radiotherapy, had significantly lower
volumes of caudate nucleus and performed significantly
worse on measures of verbal fluency in comparison with pa-
tients prior to treatment. There were no differences in the
mean volumes of total white matter, total gray matter, thala-
mus, putamen, and amygdala between the studied groups.
Conclusion In all children treated according to the ALL IC-
BFM 2002 with high-dose chemotherapy, both decreased vol-
ume of selected subcortical structures and cognitive impair-
ment was observed, especially in children who received che-
motherapy in combination with reduced dose CNS radiother-
apy. In all children treated according to the ALL IC-BFM
2002 with high-dose chemotherapy, both decreased volume
of selected subcortical structures and cognitive impairment
were observed, especially in children who received chemo-
therapy in combination with CNS radiotherapy.
Keywords Acute lymphoblastic leukemia . Brain . CNS
prophylaxis . Cognitive functioning
Introduction
Acute lymphoblastic leukemia (ALL) is the most common
malignancy in children [1–3]. Treatment of ALL in children
based on the ALL IC-BFM 2002 protocol (ALLIC 2002) is
composed of multi-drug chemotherapy adjusted for three risk
subgroups (standard, intermediate, and high) administered re-
peatedly for 24 months and central nervous system (CNS)
radiotherapy given to a particular group of patients. Even
though only 4% of the cases have CNS involvement at diag-
nosis [4], CNS-directed prophylaxis is a mandatory part of
ALL therapy in all cases due to high risk of CNS relapse [3,
5, 6]. According to ALLIC 2002, CNS prophylaxis—
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depending on risk group and immunophenotype of leuke-
mia—consists of systemic chemotherapy with intravenous
methotrexate in high or medium doses, intrathecal methotrex-
ate alone, or in combination with cytarabine and prednisone
and CNS radiotherapy at total dose of 12 Gy which is used
only in patients stratified into high-risk group and T-cell ALL.
Prior reports on cognitive assessment following cranial ra-
diotherapy at an 18-Gy dose or higher demonstrated that such
approach may lead to diminished intelligence quotient, mem-
ory, attention, and processing speed deficits [7–9]. However,
the impact of 12-Gy dose radiotherapy on cognitive function-
ing remains unknown. Some authors showed adverse effects
of methotrexate, both intrathecal [10] and intravenous [11], on
long-term neuropsychological outcome in ALL survivors,
while some others did not observe such consequences [6].
There were reports indicating leukoencephalopathy defined
as white matter (WM) hyperintensities on T2-weighted im-
ages related to methotrexate used in combination with CNS
radiotherapy [12]. Currently, there is very limited evidence
regarding impact of the therapy on gray matter (GM) struc-
tures and its relationship to cognitive performance in ALL
survivors.
However, even though there is very limited data on GM
impairment and data on association of structural imaging fea-
tures with cognitive processes in children survived from ALL
is still lacking, the role of basal ganglia is well known. Basal
ganglia are clusters of GM within the basal part of the fore-
brain. Due to the complex structural and functional connec-
tions of basal ganglia with widespread regions of the cortex,
especially with associative prefrontal cortex, they contribute
to many functions. These are selecting and enabling various
cognitive, executive, or emotional programs that are stored in
other cortical areas and involvement in certain types of learn-
ing and in the enabling of practiced motor acts as well as in
gating the initiation of voluntary movements by modulating
motor programs stored in the motor cortex. However, despite
the fact that there are some papers concerning the correlation
between cortex volume and cognitive performance in patients
who were treated with chemoradiotherapy, there is very little
data regarding the impact of subcortical structures on func-
tioning. Nevertheless, clinical studies support observa-
tions that dysfunction in individual basal ganglia loops
with the cerebral cortex may impact neurocognitive per-
formance [13].
The aim of this cross-sectional study was to evaluate the
impact of high-dosemethotrexate and 12-Gy radiation therapy
on total WM, total GM and subcortical structures volumes,
and cognitive performance in ALL children. We hypothesized
that reduced volume of the subcortical structures would be
associated with treatment effect of chemotherapy and radio-
therapy. We also hypothesized that observed cognitive deficits
would be associated with volumetric measurements of struc-
tures involved in impaired functions.
Patients and methods
Study design and patient population
This study was approved by the local Institutional Review
Board. Information about the trial was presented to potential
participants and their parents. Written informed consent was
obtained from all participants.
We retrospectively identified 98 children cured from ALL
and treated according to ALLIC 2002 between December
2002 and December 2007. Thirty-seven patients were not el-
igible for the follow-up study (19 patients relapsed; 8 patients
died because of treatment-related complications; 4 patients
had CNS involvement at ALL diagnosis; 2 had Down syn-
drome; 4 were not eligible for other causes, i.e., mental retar-
dation in 3 cases and Gypsy origin in 1 case). The other 61
children were invited to participate in the study. From this
group, 28 children did not participate (6 patients were untrace-
able and 22 declined to participate). The other 33 families
agreed to participate in the cross-sectional prospective study.
Out of the 33 children who were tested, 22 children (11 fe-
male) of median age of 12.1 years (interquartile range (IQR)
9.5–14.4, range 7.6–19.9) had previously been treated accord-
ing to standard or intermediate-risk group of ALLIC 2002
with chemotherapy alone (group I). The other 11 children (5
female) of median age of 11.6 years (IQR 8.3–13.2, range
6.7–18.6) had previously been treated according to the high-
risk group with chemotherapy and cranial radiotherapy (group
II). Flow diagram of the patients’ selection is shown in Fig. 1.
The median time from the therapy completion to the evalua-
tion was 50 months (range of 30–75 months). The control
group consisted of 12 children (5 female) of median age of
11.8 years (IQR 9.2–13.7, range 6.4–17.5) newly diagnosed
with ALL without CNS involvement and tested before the
chemotherapy and corticosteroids started (group III).
Summary of patients in each studied group is presented in
Table 1.
Therapeutic regimen
The ALLIC 2002 regimen was based on multi-drug chemo-
therapy consisting of induction therapy, consolidation,
reinduction, and maintenance therapy. The treatment intensity
had been stratified into one of three risk subgroups: standard,
intermediate, or high. Children had been stratified into the
high-risk group if one of the following factors occurred: pres-
ence of t(9;22) (BCR/ABL+) or t(4;11) (MLL/AF4+), poor
corticosteroid response (peripheral blasts count of >1 × 109/
L on day 8 of initial treatment), or lack of hematological re-
mission on day 33 (>5% of blasts in bone marrow). The re-
maining children had been classified as standard or interme-
diate risk. For all risk groups, induction therapy had included
prednisone, vincristine, daunorubicin, asparaginase,
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cyclophosphamide, cytarabine, mercaptopurine, and intrathe-
cal methotrexate. The consolidation treatment for standard
and intermediate-risk group had included intermediate doses
of methotrexate (MD-MTX; 2 g/m2) with intrathecal metho-
trexate or high doses of methotrexate (HD-MTX; 5 g/m2),
cytarabine, and vincristine. High-risk group had received
vindesine, asparaginase, cyclophosphamide or ifosfamide,
and daunorubicin, etoposide with triple intrathecal therapy
(methotrexate, cytarabine, prednisone). Reinduction therapy
had been the same for all patients and included vincristine,
doxorubicin, asparaginase, cyclophosphamide, cytarabine,
thioguanine, and intrathecal methotrexate. High-risk patients
had received 12-Gywhole-brain radiotherapy as a prophylaxis
of CNS prior to standard maintenance therapy: mercaptopu-
rine and methotrexate.
Magnetic resonance imaging—acquisition and analysis
methods
Patients were scanned using 1.5 T Magnetom Avanto scanner
(Siemens, Erlangen, Germany): standard 12-channel headma-
trix coil. Structural brain imaging was assessed using 3D T1-
weighted magnetization-prepared rapid acquisition gradient
echo sequence (TR/TE/TI = 2400/3.61/1000 ms, flip an-
gle = 8°, voxel dimensions = 1.20 × 1.25 × 1.25 mm,
Grappa = 2). Image processing was performed using FSL
(Functional Magnetic Resonance Imaging of the Brain—
FMRIB Software Library) 5.0-FMRIB’s Integrated
Registration and Segmentation Tool (FIRST) software pack-
age to obtain the volume of total WM and GM as well as
subcortical structures (thalamus, caudate, putamen,
Assessed for eligibility (n=98)












Chemo- and Radiotherapy Group (n=11)
Invited by letter (n=61)
Fig. 1 Flow diagram of ALL
survivor selection
Table 1 Characteristics of patients
Group I (chemotherapy only) Group II (radiochemotherapy) Group III (control group) p
Number (male/female) 22 (11:11) 11 (6:5) 12 (7:5) –
Range of age (median; IQR) 7.6–19.9 (12.1; 9.5–14.4) years 6.7–18.6 (11.6; 8.3–13.2) years 6.4–17.5 (11.8; 9.2–13.7) years 0.480
Time from therapy ended (median) 31.5–71.4 (50.7) months 30.0–75.2 (57.0) months – 0.689
Range of age at diagnosis
(median; IQR)
2.7–13.9 (5.2; 4.3–8.2) years 2.8–12.9 (4.9; 3.9–8.8) years – 0.633
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hippocampus, amygdala, globus pallidus, the whole brain)
[14–16]. Following registration to a standard template,
this software uses a Bayesian probabilistic model that
relies on shape and intensity to infer the location of
structures of interest. For each structure, a pre-defined
number of modes is applied to ensure the best fit.
Processing steps of FIRST included affine registration
to standard template using FMRIB’s Linear Image
Registration Tool (FLIRT), elastic registration to stan-
dard brain template using FNIRT, skull stripping using
Brain Extraction Tool (BET), and tissue-type segmenta-
tion with FMRIB’s Automated Segmentation Tool
(FAST). All files were visually inspected to ensure cor-
rect registration. A voxel count was then used to esti-
mate volumes of structures segmented (Fig. 2). Finally,
for all subcortical structures, left and right volumes
were combined and mean values of both volumes were
taken for further analysis.
Neuropsychological assessment methods
All children enrolled into the study were evaluated
using the battery of neuropsychological tests tailored
to the age of a child for assessment of different aspects
of memory, attention, concentration, processing speed
(Wechsler Intelligence Test for Children, Rey Auditory
Verbal Learning Test, verbal fluency test, and Benton
Visual Retention Test), and executive functions (Stroop
test, clock drawing test, and Wisconsin Card Sorting
Test). All neuropsychological tests were administered
in Polish standardized version, and Polish normative
conversions were used to assess the results of studied
group. Neuropsychological evaluation was scheduled on
the same day, prior to magnetic resonance imaging.
Wechsler Intelligence Test for Children (WISC-R) is the
most popular and the most widely used test to assess the in-
telligence quotient (IQ). Intelligence determines the ability to
use one’s mental abilities to operate efficiently and respond to
the changing demands of the environment [17]. The two basic
ways of intelligence are verbal and non-verbal behavior. This
was reflected in the Wechsler scale to measure intelligence in
two subscales, verbal and performance, to estimate the final
result full-scale IQ. The Ray Auditory Verbal Learning Test
(RAVLT) is widely used and frequently translated verbal
memory measure that provides scores for different aspects of
memory. The RAVLT has proven useful in detecting dysfunc-
tion in different memory systems with patterns of learning and
retrieval [18]. The verbal fluency test (VFT) is a short test
of verbal functioning. Serious deficits in either verbal abil-
ity will manifest themselves in poor performance in the
fluency tasks. Therefore, the fluency tasks can be used as
an efficient screening instrument of general verbal func-
tioning [19]. Benton Visual Retention Test (BVRT) is a
tool for measuring the visual perception, visual short-
term memory, and visuospatial cognition. BVRT allows
differentiating the visual memory disorders from attention
disorders. The Stroop test is used to assess selective atten-
tion and executive functioning. For children with poor
reading skills (below 11 years old), we used Kit for
Children of Stroop test with animal naming instead of read-
ing. The clock drawing test (CDT) is a simple and effective
test to include neuropsychological status. It also provides a
significant advance in early detection and monitoring cog-
nitive disorders. The CDT is a useful task to assess func-
tioning of multiple brain regions, in cortical and subcorti-
cal areas, and the circuits that connect them. Impaired
clock drawing can provide a signal of different cognitive
impairment [20]. Wisconsin Card Sorting Test (WCST) is
one of the most commonly used instruments for the assess-
ment of executive function and is considered a significant
measure of cognitive flexibility, attention, and executive
functioning. The test assesses abstract reasoning, the sub-
ject’s ability to generate problem-solving strategies in re-
sponse to changing conditions, and may be regarded, there-
fore, as a measure of flexibility of thought [21].
To analyze the obtained data, the neuropsychological test
results were combined within domains of cognitive function-
ing they measure, i.e., intelligence quotient, memory and at-
tention, processing speed, and executive functions.
Fig. 2 Axial (a), sagittal (b), and coronal (c) images of subcortical
segmentation obtained using FSL-FIRST tool. Label colors represent
the thalamus (green), putamen (pink), pallidum (dark blue), caudate
nucleus (light blue), amygdala (cyan), and hippocampus (yellow)
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Intelligence quotient was based onWISC-R results. Themem-
ory and attention testing took into account the Verbal
Comprehensive Index (VCI) calculated on the base of four
subtests of the WISC-R scale (similarities, vocabulary, com-
prehension, and information); RAVLTscoresmeasuring learn-
ing rate, retroactive, and proactive interference; and retention
of information and VFT in both phonemic and semantic cat-
egories. Processing speed was evaluated by the Processing
Speed Index (PSI) of WISC-R test containing results of cod-
ing and symbol search subtest and the Stroop test performance
index. Finally, executive functioning was tested by CDT total
score andWCST results (number of achieved categories, trials
needed to achieve the first category, and percentage of correct
answers).
Statistical analysis
Statistical analysis was performed using Statistica v8.0.
Neuropsychological performance was compared across sub-
groups using Mann-Whitney U test, whereas brain volumes
were compared by Student’s t test. To assess group interac-
tions in measured neuropsychological factors, we used
Kruskal-Wallis test and for volumetric measurements—
ANOVA. Uncorrected p values of ANOVA are reported
throughout the manuscript, and Bonferroni corrections for
multiple comparisons are also included where appropriate.
Outliers were adjusted by the Grubbs’ test. Finally, to examine
the relationship between neurocognitive performance and vol-
umetric assessment, the linear regression analysis was per-
formed. Statistical significance was set at p < 0.05.
Results
Demographic
The analyzed groups were comparable with regard to age
(p = 0.480) and demographic and socio-economic status
assessed by the parents’ self-assessment questionnaire.
CNS structural magnetic resonance assessment
Both treated groups, whether chemotherapy only or in com-
bination with CNS radiotherapy, had significantly lower vol-
umes of caudate nucleus (p = 0.010 and p = 0.013) in com-
parison to control group. Moreover, the group of children who
had received irradiation had smaller mean hippocampal vol-
ume than children treated without irradiation (p < 0.001) and
control group (p = 0.004). The group treated with chemother-
apy and radiotherapy had smaller mean volume of globus
pallidus (p = 0.005) when compared with patients prior to
therapy. There were no differences in the mean volumes of
total WM, total GM, thalamus, putamen, and amygdala be-
tween studied groups (Table 2). These results were also con-
firmed by ANOVA analysis with correction for multiple com-
parisons (Table 3).
Neurocognitive assessment
Comparison of the three studied groups revealed that patients
treated with chemo- and CNS radiotherapy performed worse
in memory and executive functions domain. Group II showed
Table 2 Mean subcortical volumes based on FIRST segmentation (comparisons across subgroups)

















Mean SD Mean SD Mean SD t p t p t p
Thalamus 7093 710 6710 279 7104 664 0.657 0.519 0.750 0.466 1.515 0.140
Hippocampus 4067 391 3417 220 4059 511 0.611 0.541 3.321 0.004 4.954 <0.001
Amygdala 1482 181 1402 137 1658 295 1.198 0.247 1.796 0.090 1.261 0.217
Caudate nucleus 3842 439 3796 357 4433 340 2.767 0.010 2.828 0.013 0.194 0.847
Putamen 5887 518 6015 500 5908 595 0.289 0.771 0.728 0.476 0.631 0.532
Globus pallidus 1728 235 1673 156 1957 146 1.818 0.082 3.189 0.005 1.041 0.306
Gray matter 658872 60581 680733 51924 668637 59581 0.386 0.703 0.398 0.696 0.814 0.424
White matter 499963 42262 497747 43763 524515 49034 1.312 0.201 1.062 0.306 0.113 0.911
Brain ventricles 7906 1421 7488 1470 9625 2599 4.322 0.001 3.792 0.001 0.788 0.437
All data given is raw scores (absolute volumes of brain structures)
Values in italics has statistical significance set at p < 0.05
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significantly worse long-term memory VCI (score 46.0+/
−18.0 vs 44.0+/−9.0 and 59.0 +/−25.0; p = 0.047) and post-
poned recalling in RAVLT (p = 0.026) and worse visual-
spatial memory (p = 0.005) in comparison with control group
and group treated with chemotherapy alone. In addition, these
patients performed significantly worse in executive function-
ingmeasured by achieved categories and percentage of correct
answers in WCST (p = 0.011 and p = 0.012, respectively).
Both studied groups, I and II, showed similar phonemic (8.7
and 7.7 vs 10.9) but worse semantic verbal fluency (17.5 and
15.0 vs 24.0) in contrast to the control group (p = 0.095 and
p < 0.001, respectively). The group of patients who had not
received CNS radiotherapy was found to have significantly
worse results in interfering trial of RAVLT (p = 0.004) and
Stroop test index (p < 0.001) compared with children before
therapy. Furthermore, the significant difference between both
treated groups (group I vs II) was found in the IQ assessment
(p < 0.001) and the processing speed (p = 0.015). In addition,
the Kruskal-Wallis test revealed significant interactions be-
tween groups for memory, attention, and executive functions.
The summary of neuropsychological assessment results is giv-
en in Table 4.
Subcortical gray matter volume and cognitive
performance
Regression of memory, attention (VCI, RAVLT recalling,
and BVRT), executive functions (WCST), and volumetric
measurements revealed a significant relationship between
auditory-verbal memory and hippocampus volume regard-
l e s s o f app l i ed the r apy (Tab l e 5 ) . The o the r
neurocognitive functions analyzed were not associated
with brain volumes.
Discussion
Our study has shown that all treated patients have decreased
cognitive performance in comparison to ALL patients prior to
treatment. They also have decreased hippocampal and caudate
nucleus volumes. The therapeutic regimen of childhood ALL
assumes diverse CNS involvement prophylaxis depending on
risk group, i.e., with or without radiotherapy. Results of the
study demonstrated that all included patients treated for ALL,
regardless of whether or not irradiated, in contrast to some
other reports and despite expectations of the ALLIC 2002
protocol users, do have cognitive functioning impairment
and decreased volume of subcortical GM in hippocampus
and caudate nucleus in long-term follow-up. Irradiated pa-
tients performed worse in both long-term and short-term
memory, attention, and executive tasks.
In the study, patients treated with CNS irradiations were
proven to have smaller hippocampus volumes in comparison
with children treated with chemotherapy only and the control
group. The main reason for selecting hippocampal volume as
imaging outcome was its crucial role for memory processing
and encoding declarative memories. The domains of
radiation-related neurocognitive decline encompass immedi-
ate and delayed verbal memory with or without non-verbal
memory [22]. However, Sun et al. [23] reported that even
though verbal memory was likely to deteriorate significantly,
general non-specific cognitive functions were not influenced.
Our results provided the same conclusions that only selected
cognitive functions were significantly affected in ALL survi-
vors, while IQ levels were comparable with IQ levels of the
control group. As given in the literature, in our study, the
most affected cognitive domains were those related to
the hippocampal area, i.e., immediate and delayed ver-
bal memory.
Table 3 Mean subcortical
volumes based on FIRST
segmentation (group interactions)
Brain structure (mean volume) Group interaction (ANOVA) Post hoc correction (Bonferroni test)
I vs III II vs III I vs II
F puncorr pBon pBon pBon
Thalamus 1.162 0.327 0.999 0.669 0.442
Hippocampus 10.449 <0.001 0.999 <0.001 <0.001
Amygdala 2.013 0.148 0.172 0.420 0.964
Caudate nucleus 5.008 0.013 0.002 0.006 0.998
Putamen 0.376 0.789 0.998 0.999 0.996
Globus pallidus 3.546 0.047 0.260 0.006 0.859
Gray matter 0.338 0.716 0.999 0.999 0.999
White matter 0.987 0.384 0.602 0.783 0.999
Brain ventricles 12.126 <0.001 <0.001 <0.001 0.999
puncorr p value for group interaction measured by ANOVA, pBon p value corrected for multiple comparisons by
Bonferroni test
Values in italics has statistical significance set at p < 0.05
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The mechanism of cognitive decline after irradiation of hip-
pocampal area remains unclear. It is well known that the hip-
pocampi are extremely vulnerable to chemotherapy and radio-
therapy [24–27]. Injury of neuronal stem cells located in the
hippocampal region might contribute to long-term impact on
cognitive processing. The cognitive impairment after radio-
therapy results from inhibition of hippocampal neurogenesis.
Cheng et al. [28] suggest that despite aging-associated decline,
the neurogenesis may be further inhibited by ablation of neural
progenitors and activation of microglia in hippocampus caused
by irradiation. This may explain the results of our study and
correlation between hippocampus injury and memory deficits
in patients who were irradiated. These deficits were not found
in children who did not receive cranial irradiation.
We also found a significant reduction of caudate volume in
both groups of ALL survivors treated with or without irradiation.
The caudate, as part of the striatum, is a part of the frontostriatal
circuit supporting executive functions [29], and caudate lesions
have been shown to lead to impaired processing speed, attention,
learning, memory, and verbal fluency [30, 31]. Remarkably,
these functions were also found to be affected in our cohort.
Globus pallidus is typically associated with motor deficits,
including Parkinsonism, tremor, and dystonia. However, less
commonly known, this area may also be associated with cog-
nitive functioning. Cognitive domains related to pallidum area
include executive functions and verbal memory [32].
Dysfunction of globus pallidus results in worsening general
cognition, immediate recall problems, and deterioration of ex-
ecutive functions [33]. In our study, the worse executive func-
tions performance found in irradiated ALL survivors may be
related to smaller pallidum volume in this group of patients.
Table 5 Linear model regress ion analys is of se lec ted
neuropsychological domains as a function of hippocampus volume
Cognitive domain Beta coefficients p
Memory and attention
VCI 0.218 0.186
RAVLT recall 0.614 0.004
BVRT 0.168 0.279
Executive functions
WCST achieved cat. 0.063 0.714
Values in italics has statistical significance set at p < 0.05
Table 4 Summary of neuropsychological assessment
Domain/test I
Chemotherapy


























Median IQR Median IQR Median IQR Z p Z p Z p Chi p
IQ assessment
WISC-R 114.0 25.0 102.0 14.0 120 34.0 0.298 0.916 0.688 0.497 2.641 <0.001 0.987 0.844
Memory and attention
VCI 44.0 9.0 46.0 18.0 59.0 25.0 1.446 0.159 2.101 0.047 1.069 0.285 2.256 0.498
RAVLT learning 7.0 3.0 6.0 3.0 8.0 1.0 1.829 0.156 1.287 0.189 0.592 0.554 5.485 0.116
RAVLT interference 11.0 3.0 8.0 2.4 9.0 1.0 2.059 0.004 0.534 0.597 3.418 <0.001 17.589 <0.001
RAVLT recall 11.0 2.0 7.0 3.0 10.0 2.0 0.894 0.377 2.459 0.026 3.437 <0.001 7.598 0.017
BVRT 7.5 3.0 6.0 2.0 8.5 1.0 1.889 0.072 2.947 0.005 1.852 0.064 6.856 0.122
VFT phonemic 8.7 1.7 7.7 4.7 10.9 3.0 2.894 0.013 2.259 0.031 1.375 0.169 5.688 0.095
VFT semantic 17.5 4.0 15.0 4.0 24.0 5.0 2.987 <0.001 2.984 <0.001 3.684 <0.001 17.459 <0.001
Processing speed
PSI 24.0 5.0 21.0 4.0 24.0 2.0 0.784 0.624 1.008 0.584 2.444 0.015 3.468 0.415
Stroop test 2.9 0.4 3.2 1.0 2.5 0.3 2.718 <0.001 0.064 0.083 1.071 0.284 7.895 0.018
Executive functions
CDT 3.0 1.0 2.0 1.0 3.0 0 1.110 0.267 1.671 0.094 0.897 0.369 0.001 1.000
WCST achieved cat. 4.5 1.0 3.0 2.0 5.0 1.5 1.658 0.099 2.947 0.011 2.081 0.037 13.259 0.004
WSCT trials to first cat. 16.0 11.0 19.0 12.0 12.0 4.0 1.386 0.201 1.724 0.136 0.573 0.567 4.658 0.198
WSCT percentage of correct
answers
56.6 19.6 38.0 21.0 66.3 17.5 1.784 0.074 2.891 0.012 1.375 0.169 6.314 0.126
All data given in the table is scaled scores (adjusted for the children’s age)
Values in italics has statistical significance set at p < 0.05
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The literature data on WM and GM volume changes after
childhood ALL treatment remains unclear. In our study, we
found no statistical differences in total WM and GM volumes
between both studied groups and the control group. However,
there was a trend to smaller WM volume in both treated
groups. Other authors also reported smaller WM volumes in
ALL survivors [34–36]. Reddick et al. [34] have previously
attempted to address the brain volume reduction as a result of
ALL therapy, and they have found smaller WM volumes and
no differences in GM volumes, even in children receiving
18 Gy when compared to healthy controls. However,
Reddick et al’s structural analysis did not assess subcortical
structures, but only total GM. Similarly, Kesler et al. [35]
found no difference in total brain volume but significantly
reduced regional WM volumes in ALL survivors compared
with the controls. Finally, Carey et al. [36] described two
specific regions of reduced WM in the right frontal lobe in
ALL survivors compared with healthy controls. In previous
studies of ALL patients, there was little focus on regional GM,
especially on subcortical structures. Porto et al. [37] reported
reduced GM concentration within the caudate and thalamus in
irradiated survivors of childhood ALL, while Zeller et al. [38]
found that ALL survivors had significantly smaller volumes
of cortical GM, amygdala, caudate, hippocampus, and thala-
mus compared with healthy controls. In the study, we showed
smaller volume of hippocampus, caudate, and globus pallidus
in irradiated ALL survivors with no difference in total GM
volumes. The reason for these differences between studies
may be related to technical difficulties segmenting small struc-
tures such as the hippocampus.Moreover, between these stud-
ies, there are imaging parameter differences, i.e., other scan-
ners’ parameters and acquisition time.
The mechanism of neurotoxic consequences of ALL ther-
apy is complex. There are two explanations considering de-
creased volumes of brain. One mechanism is damage to oli-
godendroglial cells resulting in demyelination and another
atypical WM development [39]. The other possible mecha-
nism is vascular damage. Methotrexate inhibits enzymes in-
volved in folic acid biosynthesis. Decreased folate causes el-
evation of homocysteine, an amino acid toxic for blood vessel
endothelium. The final result is microangiopathy of small
blood vessels with its occlusion, particularly vulnerable in
the basal ganglia vessels [40, 41]. Selective vulnerability of
neuronal and glial cell populations implicates that certain sub-
groups of cells will die shortly following therapy, and remain-
ing intact cells will reorganize cytoarchitectonic structure of
both GM and WM. However, GM reorganization might also
play a more important role in affecting developmental trajec-
tory, as well as WM role that is well proven.
In our study, the children treated with chemotherapy alone
were also found to have cognitive deficits. Even though they
achieved results comparable to control group in the intelli-
gence test, long-term and short-term memory domain, they
had significantly lower processing speed than the control
group. However, previous papers usually connected slowed
profile information processing with a consequence of radio-
therapy; it is uncertain if chemotherapy alone may also cause
this cognitive dysfunction [42–47]. Possible explanation giv-
en in the literature is decreased cerebral volume, which is
associated with poorer cognitive outcome, especially slow
processing, and attention problems [48]. Although WM loss
is greater in children treated with radiotherapy, its volumes in
ALL survivors treated with chemotherapy are decreased only
in relation to the control groups in many reports [34, 44, 49,
50]. In our study, there was also the trend to smaller volumes
in both treated groups when compared to controls, but due to
the small sample size, it was not statistically confirmed.
Executive function performance was significantly worse in
children who had previously received irradiation in contrast to
children treated with chemotherapy alone. Other results were
found in Buizer et al.’s [51, 52] studies, who found that exec-
utive function deficits are a main feature in ALL survivors
treated with chemotherapy alone. The explanation may be
the higher dose of chemotherapy (MTX) in the group treated
with irradiation than in the group treated with chemotherapy
alone in our study. The cumulative dose of intravenous meth-
otrexate correlates with the severity of deficits. Executive
functioning is based on networks localized in cerebellar pre-
frontal area. The myelination of the prefrontal cortex has a
protracted course during childhood and adolescence [26,
53]. The less mature brain seems to be more vulnerable
to chemotherapy-induced damage than the more mature
areas. Thus, prefrontal cortex defects and its functional
implications, i.e., executive function deficits, are ob-
served in all children treated due to ALL, even in those
treated without irradiation [53].
Our study is limited due to a small number of patients and
cross-sectional design. Further multi-center studies on larger
groups of patients are necessary to confirm our preliminary
results. Another limitation is the cross-sectional design of the
study and lack of information on structural brain changes oc-
curring prior to diagnosis and at the time of the treatment
initiation. Furthermore, the structural imaging had relatively
large voxels which would result in partial voluming in small
convoluted structures, such as hippocampus. Nevertheless, we
propose that detailed structural assessment of regional brain
volume is possible in clinical settings provided that an MRI
study will include a volumetric sequence that enables more
detailed analysis like the one used in this study.
Our results are preliminary and only the first step to assess
long-term side effects of high-dose methotrexate administered
alone or in combination with cranial irradiation in dose re-
duced to 12 Gy as a CNS prophylaxis in ALL children.
Further studies should also focus on finding the mechanism
of brain damage by examining the functional connectivity and
structural features of the neuronal pathways.
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In summary, our results provide the first assessment of
long-term brain structural magnetic resonance imaging results
and neurocognitive functioning of children treated according
to ALLIC 2002. These late effects are even more pronounced
in children treated with CNS radiotherapy. It seems to be es-
sential to further reduce the role of irradiation as part of CNS
prophylaxis in children treated for ALL. Further studies based
on a larger group of patients are necessary to confirm these
observations.
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